Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 18/20 | 0.59 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | CCNK | O75909 | 1/20 | 0.50 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | CCND3 | P30281 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14481942 | 0.89 | BRD4 (0.50) | BRD4EGFRJAK2FLT3CDK2 | |
| SCHEMBL12854445 | 0.85 | BRD4 (0.57) | BRD4EGFRJAK2FLT3 | |
| SCHEMBL14481732 | 0.84 | BRD4 (0.58) | BRD4EGFRJAK2FLT3CCNK | |
| SCHEMBL12854446 | 0.80 | BRD4 (0.57) | BRD4EGFRJAK2FLT3CDK2 | |
| SCHEMBL3111599 | 0.79 | BRD4 (0.61) | BRD4EGFRJAK2FLT3 | |
| SCHEMBL13268027 | 0.79 | BRD4 (0.58) | BRD4EGFRJAK2FLT3 | |
| SCHEMBL12854449 | 0.77 | PDGFRB (0.52) | BRD4JAK2FLT3CCNKCCNA2 | |
| SCHEMBL13268017 | 0.77 | BRD4 (0.58) | BRD4EGFRJAK2FLT3 | |
| SCHEMBL3118349 | 0.76 | BRD4 (0.57) | BRD4JAK2FLT3 | |
| SCHEMBL31163056 | 0.76 | BRD4 (0.76) | BRD4EGFRJAK2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8518937-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. | 2013-01-10 | — | — | US | disclosed |
| US-8278299-B2 | Pyrimidinediamine kinase inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012501-A1 | PYRIMIDINEDIAMINE KINASE INHIBITORS | PLK1, TK1, DTYMK | BRD4 758/4885EGFR 1807/4885JAK2 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.